Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
BUR's Cash to Debt is ranked higher than
79% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. BUR: No Debt )
BUR' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.90
BUR's Equity to Asset is ranked higher than
91% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BUR: 0.90 )
BUR' s 10-Year Equity to Asset Range
Min: 0.84   Max: 0.94
Current: 0.9

0.84
0.94
Interest Coverage No Debt
BUR's Interest Coverage is ranked higher than
63% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BUR: No Debt )
BUR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 76.03
M-Score: 2.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6480.41
BUR's Operating margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. BUR: -6480.41 )
BUR' s 10-Year Operating margin (%) Range
Min: -18770   Max: -6582.11
Current: -6480.41

-18770
-6582.11
Net-margin (%) -6174.23
BUR's Net-margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. BUR: -6174.23 )
BUR' s 10-Year Net-margin (%) Range
Min: -18486.67   Max: -6275.79
Current: -6174.23

-18486.67
-6275.79
ROE (%) -95.80
BUR's ROE (%) is ranked higher than
59% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. BUR: -95.80 )
BUR' s 10-Year ROE (%) Range
Min: -94.57   Max: -22.1
Current: -95.8

-94.57
-22.1
ROA (%) -85.36
BUR's ROA (%) is ranked higher than
56% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. BUR: -85.36 )
BUR' s 10-Year ROA (%) Range
Min: -89.62   Max: -21.77
Current: -85.36

-89.62
-21.77
ROC (Joel Greenblatt) (%) -942.99
BUR's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. BUR: -942.99 )
BUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1207.15   Max: -167.13
Current: -942.99

-1207.15
-167.13
EBITDA Growth (3Y)(%) -15.70
BUR's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BUR: -15.70 )
BUR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 49.4
Current: -15.7

0
49.4
EPS Growth (3Y)(%) -14.10
BUR's EPS Growth (3Y)(%) is ranked higher than
72% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. BUR: -14.10 )
BUR' s 10-Year EPS Growth (3Y)(%) Range
Min: -18.1   Max: 326.4
Current: -14.1

-18.1
326.4
» BUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BUR Guru Trades in Q1 2014

Chuck Royce 419,903 sh (unchged)
» More
Q2 2014

BUR Guru Trades in Q2 2014

Chuck Royce 433,253 sh (+3.18%)
» More
Q3 2014

BUR Guru Trades in Q3 2014

Chuck Royce 419,903 sh (-3.08%)
» More
Q4 2014

BUR Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 11.53
BUR's Forward P/E is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BUR: 11.53 )
N/A
P/B 16.50
BUR's P/B is ranked higher than
59% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. BUR: 16.50 )
BUR' s 10-Year P/B Range
Min: 0   Max: 31.3
Current: 16.5

0
31.3
EV-to-EBIT -17.31
BUR's EV-to-EBIT is ranked higher than
64% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BUR: -17.31 )
BUR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -17.31

Current Ratio 6.06
BUR's Current Ratio is ranked higher than
74% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. BUR: 6.06 )
BUR' s 10-Year Current Ratio Range
Min: 1.38   Max: 55.01
Current: 6.06

1.38
55.01
Quick Ratio 6.06
BUR's Quick Ratio is ranked higher than
75% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. BUR: 6.06 )
BUR' s 10-Year Quick Ratio Range
Min: 1.38   Max: 55.01
Current: 6.06

1.38
55.01
Days Sales Outstanding 545.62
BUR's Days Sales Outstanding is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. BUR: 545.62 )
BUR' s 10-Year Days Sales Outstanding Range
Min: 425.83   Max: 541.74
Current: 545.62

425.83
541.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 33.10
BUR's Price/Net Cash is ranked higher than
75% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. BUR: 33.10 )
BUR' s 10-Year Price/Net Cash Range
Min: 2.6   Max: 204.5
Current: 33.1

2.6
204.5
Price/Net Current Asset Value 29.40
BUR's Price/Net Current Asset Value is ranked higher than
73% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. BUR: 29.40 )
BUR' s 10-Year Price/Net Current Asset Value Range
Min: 2.55   Max: 136.33
Current: 29.4

2.55
136.33
Price/Tangible Book 20.40
BUR's Price/Tangible Book is ranked higher than
62% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. BUR: 20.40 )
BUR' s 10-Year Price/Tangible Book Range
Min: 2.41   Max: 57.79
Current: 20.4

2.41
57.79
Earnings Yield (Greenblatt) -5.80
BUR's Earnings Yield (Greenblatt) is ranked higher than
73% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BUR: -5.80 )
BUR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.2   Max: 0
Current: -5.8

-9.2
0

Analyst Estimate

Mar15 Mar16
EPS($) -0.14 0.19
EPS without NRI($) -0.14 0.19

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BU.Canada, BNE.Germany,
Burcon NutraScience Corp was incorporated on November 3, 1998. The Company, through its subsidiary, Burcon NutraScience (MB) Corp. is a research and development company building a portfolio of composition, application and process patents around its plant protein extraction and purification technology. The Company's products include CLARISOY, a soy protein isolate, which is used in various food products, including protein shakes, power bars, soups and sauces, meats and meat analogs, and breads and baked foods; and PEAZAZZ, a soluble pea protein isolate. Its products also comprise canola protein isolates, such as Supertein that comprises albumin proteins used in beverages, confectionery, aerated desserts, and protein bars; Puratein, which consists of globulin proteins used in dressings and sauces, meat substitutes, baked goods, and protein bars.
» More Articles for BUR

Headlines

Articles On GuruFocus.com
Burelle: A Growing Euro for 50 cents Mar 12 2013 

More From Other Websites
BURCON TO PRESENT AT THE 27TH ANNUAL ROTH CONFERENCE ON MARCH 10, 2015 Mar 02 2015
Burcon to Present at the 27th Annual ROTH Conference on March 10, 2015 Mar 02 2015
Will Sysco Win Antitrust Lawsuit on US Foods Deal? - Analyst Blog Feb 23 2015
Burcon reports 3Q loss Feb 17 2015
Burcon reports 3Q loss Feb 17 2015
BURCON REPORTS FISCAL 2015 THIRD QUARTER RESULTS Feb 16 2015
Burcon Reports Fiscal 2015 Third Quarter Results Feb 16 2015
Campbell Soup Falls on Weaker Sales and Profit Projections - Analyst Blog Feb 13 2015
J.M. Smucker Q3 Earnings Beat, Sales Miss as Volumes Fall - Analyst Blog Feb 13 2015
Burcon Sets Third Fiscal Quarter 2015 Conference Call for Tuesday February 17, 2015 at 2:00 p.m. ET Feb 10 2015
McCormick (MKC) Beats Q4 Earnings on CCI Cost Savings - Analyst Blog Jan 28 2015
Burcon Closes US$1.65 Million Private Placement Jan 22 2015
Sysco (SYY) Grows on Acquisitions Despite Margin Pressure - Analyst Blog Jan 19 2015
BURCON REPORTS FISCAL 2015 SECOND QUARTER RESULTS Nov 13 2014
Burcon Sets Second Fiscal Quarter 2015 Conference Call for Thursday, November 13, 2014 at 5:00 p.m.... Nov 03 2014
3rd Annual Gateway Conference to Feature Select Group of Canadian-Listed Growth Companies on... Aug 06 2014
3rd Annual Gateway Conference to Showcase More Than 60 High-Growth Public Companies in San Francisco... Jul 21 2014
BURCON NUTRASCIENCE CORP Financials Jun 28 2014
ADM ANNOUNCES INTENTION TO EXPAND COMMERCIAL PRODUCTION OF CLARISOY™ Mar 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK